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Background: ACE-I are universally recommended in patients with CHD/AMI and proved to improve acute and long-term outcome. Zofenopril has 
peculiar pharmacological characteristics that improved clinical outcome in the SMILE studies.
Methods: Study primary objective was review cumulative efficacy of zofenopril in 3630 patients with CHD enrolled over 15 years of SMILE project. 
We cumulatively examined results of SMILE 1-4 studies to assess the impact of zofenopril on 1-year CV mortality and morbidity versus placebo or 
active controls (lisinopril, ramipril). Secondary outcomes were the effects of zofenopril in different subgroups defined by: 1) demography, 2) type of 
control, 3) type of event, 4) cause of death, 5) LVEF 6) rate of hospital admission and 7) concomitant treatment.
Results: 42.9% of patients were enrolled in SMILE-1, 57.1% in SMILE II-IV studies. Mean age was 61.5±10 ys with no differences among 
subgroups. CV mortality was largely reduced by zofenopril when versus placebo (OR=0.42, 95% CI= .32-.56) with no significant differences between 
zofenopril and other ACE-I’s. Combined occurrence of mortality and morbidity was significantly reduced in patients treated with zofenopril both 
versus placebo (p<0.001) and ACEI’s (p<0.001) because of a lower rate of hospital admission. Furthermore event-free survival time was significantly 
increased in patients treated with zofenopril versus other ACEI’s (10.4; 95% CI=10.1-10.5 months vs. 8.9; 95% CI= 8.4-9.4 months; p<0.0001). No 
major differences were observed in terms of study outcome in different subgroups according to age, gender, clinical history, LVEF and concomitant 
treatment.
Conclusions: Results of SMILE-OVERALL analysis confirm the favorable effects of zofenopril treatment in patients with CHD. Reduction in mortality 
and morbidity observed in zofenopril group in comparison to placebo and other ACEI’s support that both ACE-I and pharmacological profile 
specifically contribute to the unbeated efficacy of ACE-is in CHD.
